Sandra Brosda

University of Queensland

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (15)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (11)

Riccardo Dolcetti

Head, Clinical and Translational Immunotherapy

Peter MacCallum Cancer Centre

AUSTRALIA

View details

Thomas Stoll

QIMR Berghofer Medical Research Institute

AUSTRALIA

View details

Christos S. Karapetis

AUSTRALIA

View details

Cameron Snell

Head of Anatomical Pathology

Peter MacCallum Cancer Centre

AUSTRALIA

View details

Jessica Ng

AUSTRALIA

View details

Wayne Phillips

Adjunct Professor

Monash Health

AUSTRALIA

View details

Olga Kondrashova

Team Head, Molecular Oncology

QIMR Berghofer Medical Research Institute

AUSTRALIA

View details

Kelly A Loffler

Flinders University

AUSTRALIA

View details

Iain Thomson

University of Queensland

AUSTRALIA

View details

Michelle M. Hill

The University of Queensland Diamantina Institute

AUSTRALIA

View details

colm keane

Lab head

University of Queensland

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sandra Brosda

Research Interests

Explore related searches

Contact this professor

Articles (15)

Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy

C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank

Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma

Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid‐induced DNA damage

ctDNA as a biomarker of progression in oesophageal adenocarcinoma

C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett’s Esophagus and Esophageal Adenocarcinoma

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Complications and survival after hybrid and fully minimally invasive oesophagectomy

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients

Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy

Collaborators (11)

Riccardo Dolcetti

Thomas Stoll

Christos S. Karapetis

Cameron Snell

Jessica Ng

Wayne Phillips

Olga Kondrashova

Kelly A Loffler

Iain Thomson

Michelle M. Hill

colm keane

Make your next move.